%0 Journal Article
%T Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions
%A Adrian G. Selim
%A Andrew S. Moore
%J The Journal of Molecular Diagnostics
%D 2018
%R 10.1016/j.jmoldx.2018.03.005
%X The ability to sensitively monitor minimal residual disease (MRD) has played a key
role in improving the management and outcomes for a number of leukemias, particularly
acute promyelocytic leukemia and childhood acute lymphoblastic leukemia. By contrast,
MRD monitoring in acute myeloid leukemia (AML) has been limited by variable assay
methodologies and a relative paucity of patient-specific MRD markers. Inter- and intratumor
genetic heterogeneity poses significant challenges for the identification of molecular
markers suitable for MRD monitoring in AML, particularly for those cases without structural
chromosomal rearrangements associated with fusion genes.
%U https://jmd.amjpathol.org/article/S1525-1578(17)30485-3/fulltext